Gene Therapy News

Edinburgh, United Kingdom 10th September, 2010. Synpromics announces its incorporation as Scotland’s latest biotech company. The new company aims to focus its activities in the area of synthetic mammalian biology and has acquired a number of patent applications that arose out of inventions by its founder and managing director; Dr Michael Leslie Roberts.

Living Cell Technologies Receives Grant from the Juvenile Diabetes Research Foundation International for DIABECELL® NZ Clinical Trial

29 April 2010 – Sydney, Australia, Auckland, New Zealand– Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) announced today the quarterly cash flow report for the quarter ended 31 March 2010. The Appendix 4C is attached. The cash balance at the end of the quarter was $4,090,696 compared to $5,494,841 at 31 December 2009. This decrease reflects the development of the lead product DIABECELL®.

Net operating cash outflows were $1,257,133 compared to $1,676,991 last quarter.